velpatasvir
E409693
Velpatasvir is a direct-acting antiviral medication used in combination with sofosbuvir to treat chronic hepatitis C virus infection across multiple genotypes.
All labels observed (1)
| Label | Occurrences |
|---|---|
| velpatasvir canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T4050921 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: velpatasvir Context triple: [Gilead Sciences, developed, velpatasvir]
-
A.
Waylivra
Waylivra is a prescription antisense oligonucleotide therapy used to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels in the blood.
-
B.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
C.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
D.
Novafora
Novafora was a semiconductor company known for acquiring Transmeta to expand its presence in low-power microprocessor and video processing technologies.
-
E.
Visperad
Visperad is a Zoroastrian liturgical text and ceremony that expands upon the Yasna ritual with additional invocations to various divine beings.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: velpatasvir Target entity description: Velpatasvir is a direct-acting antiviral medication used in combination with sofosbuvir to treat chronic hepatitis C virus infection across multiple genotypes.
-
A.
Waylivra
Waylivra is a prescription antisense oligonucleotide therapy used to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels in the blood.
-
B.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
C.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
D.
Novafora
Novafora was a semiconductor company known for acquiring Transmeta to expand its presence in low-power microprocessor and video processing technologies.
-
E.
Visperad
Visperad is a Zoroastrian liturgical text and ceremony that expands upon the Yasna ritual with additional invocations to various divine beings.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
NS5A inhibitor
ⓘ
antiviral drug ⓘ direct-acting antiviral ⓘ hepatitis C treatment ⓘ small molecule ⓘ |
| adverseEffect |
anemia (when combined with ribavirin)
ⓘ
fatigue ⓘ headache ⓘ insomnia ⓘ nausea ⓘ |
| approvalYear | 2016 ⓘ |
| approvedBy |
European Medicines Agency
ⓘ
Food and Drug Administration ⓘ
surface form:
U.S. Food and Drug Administration
|
| ATCCode | J05AP55 ⓘ |
| bindsTo | human plasma proteins ⓘ |
| cautionIn |
patients with decompensated cirrhosis
ⓘ
patients with severe renal impairment ⓘ |
| contraindicatedWith |
strong CYP2B6 inducers
ⓘ
strong CYP2C8 inducers ⓘ strong CYP3A4 inducers ⓘ strong P-glycoprotein inducers ⓘ |
| developedBy |
Gilead Sciences (board member)
ⓘ
surface form:
Gilead Sciences
|
| drugClass | antiviral for systemic use ⓘ |
| effectiveIn |
patients with compensated cirrhosis
ⓘ
patients without cirrhosis ⓘ |
| hasMolecularTarget | hepatitis C virus replication complex ⓘ |
| hasPregnancyCategory | use only if potential benefit justifies potential risk ⓘ |
| hasTradeName | Epclusa ⓘ |
| indicatedFor |
chronic hepatitis C genotype 1
ⓘ
chronic hepatitis C genotype 2 ⓘ chronic hepatitis C genotype 3 ⓘ chronic hepatitis C genotype 4 ⓘ chronic hepatitis C genotype 5 ⓘ chronic hepatitis C genotype 6 ⓘ pan-genotypic hepatitis C treatment ⓘ |
| isComponentOf | sofosbuvir-velpatasvir fixed-dose combination ⓘ |
| legalStatus | prescription-only ⓘ |
| metabolizedBy |
CYP2B6
ⓘ
CYP2C8 ⓘ CYP3A4 ⓘ |
| outcome | sustained virologic response in many patients ⓘ |
| reduces | hepatitis C viral load ⓘ |
| routeOfAdministration | oral ⓘ |
| takenOnceDailyWith | sofosbuvir ⓘ |
| targets | HCV NS5A protein ⓘ |
| typicalTreatmentDuration | 12 weeks ⓘ |
| usedFor | treatment of chronic hepatitis C virus infection ⓘ |
| usedWith |
Sovaldi
ⓘ
surface form:
Sofosbuvir
|
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: velpatasvir Description of subject: Velpatasvir is a direct-acting antiviral medication used in combination with sofosbuvir to treat chronic hepatitis C virus infection across multiple genotypes.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.
subject surface form:
Gilead Sciences